Targeted Protein Degradation - The Story So Far
Cellular Principles of Targeted Protein Degradation
E3 Ubiquitin Ligases as Molecular Machines and Platforms for Drug
Development
A Structural and Biophysical Perspective of Degrader Activity
through Ternary Complex Formation
Computational Modeling of PROTAC Ternary Complexes and Linker
Design
Molecular Glue Degraders: From Serendipity to Hunting and
Design
Targeted Protein Degradation as a Therapeutic Strategy in
Neurodegenerative Diseases
Insights and Future Perspectives of Covalent Protein Degraders
Extending the Degradation Toolkit - mRNA targeting as Alternative
Means to Affect Protein Levels
The Future of Heterobifunctional Compounds: PROTACs and Beyond
Destruction with a Purpose: Targeted Protein Degradation in Drug
Discovery
Taming the Beast: How to Optimize DMPK-PD Properties of Oral
Degraders
PROTAC® Protein Degraders: Bridging the Divide from Chemical
Biology Tools to Clinical Candidates
Philipp Cromm studied Chemistry at the Technical University Munich where he worked in the group of Horst Kessler. For his master's thesis he spent time with David J. Craik at the Institute for Molecular Bioscience and received his PhD under guidance of Herbert Waldmann at the Max-Planck-Institute for Molecular Physiology. Thereafter, he carried out postdoctoral studies in the group of Craig Crews at Yale University working on targeted protein degradation. In 2018 Philipp joined Bayer AG as a Medicinal Chemist.
![]() |
Ask a Question About this Product More... |
![]() |